Clinical Trials Directory

Trials / Unknown

UnknownNCT05776732

Effect of CaviionTM Precaution Medical Adhesive-related Skin Injury in Tumor Patients With PICC Catherizaion

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
165 (estimated)
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Malignant tumor patients are at high risk of medical adhesive-related skin injury(MARSI).MARSI can cause local skin ulceration, increase the difficulty of fixation and maintenance frequency, even cause unplanned extubation, and increase the pain and economic burden of the patient's re-installation.Malignant tumor patients with long-term PICC are prone to MARSI.CaviionTM can form a protective film on the skin.Applying CaviionTM before using the adhesive can effectively protect the skin and reduce the occurrence of rash.In China, CaviionTM is mostly used in infants and young children, but adults lack corresponding report and application data.Therefore, it is necessary to carry out corresponding randomized controlled study on adult patients, especially malignant tumors

Detailed description

The incidence of medical viscose-related skin injury after PICC intubation is as high as 33.15%. The main types of injury are mechanical injury, moisture-related skin injury, contact dermatitis 8.02%, folliculitis.After radiotherapy and chemotherapy, patients with malignant tumors interfere with the formation of new damaged skin cells.Large doses of immunosuppressive agents further weaken the skin barrier and are prone to skin metabolism and immune function disorder.In this study, patients with malignant tumor after PICC intubation were randomly assigned.The experimental group uses CaviionTM, and the control group does not use CaviionTM. Observe the skin condition one month after the tube placement

Conditions

Interventions

TypeNameDescription
OTHER3M CaviionTM3M CaviionTM is mainly composed of acrylate trimer, non-toxic, alcohol-free, and compatible with chlorhexidine gluconate and povidone iodine.

Timeline

Start date
2022-03-07
Primary completion
2023-10-30
Completion
2023-12-30
First posted
2023-03-20
Last updated
2023-03-20

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05776732. Inclusion in this directory is not an endorsement.